Industry News
Research, Science & Manufacturer Updates
COVID Articles
The CoVIg-19 Plasma Alliance now includes 11 plasma companies, and now also includes global organizations from outside the plasma industry.
Because research has shown the Bacillus Calmette-Guérin (BCG) tuberculosis vaccine boosts production of immune cells, it is currently being trialed in people as potential protection against COVID-19.
Octapharma USA is supporting a new investigator-initiated clinical trial led by George Sakoulas, MD, of Sharp Memorial Hospital in San Diego, Calif., focused on treating the most critical coronavirus patients who are experiencing respiratory failure who become ventilator dependent.
Novartis has initiated a Phase III clinical trial to examine the efficacy of utilizing canakinumab (Ilaris), an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia.
Inato, a marketplace that helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials, has unveiled its anticovid platform, a comprehensive, central repository for all existing clinical trials for SARS-CoV 2 (the virus that causes COVID-19).
Epidemiological data suggests populations with the highest measles-mumps-rubella (MMR) vaccination rates often have the fewest deaths from COVID-19.
The U.S. Department of Health and Human Services (HHS) is using a $100 billion hospital and provider relief fund to pay hospitals at Medicare rates for uncompensated COVID-19 care for uninsured individuals.
The U.S. Food and Drug Administration (FDA) is taking critical actions to advance development of novel coronavirus medical countermeasures.